多发性肌炎与皮肌炎患者间质性肺病患病率的荟萃分析(2000–2020)
该荟萃分析纳入2000年至2020年发表的34项研究、共10,130例多发性肌炎(PM)/皮肌炎(DM)患者,采用随机效应模型合并间质性肺病(ILD)患病率。全球PM/DM患者ILD合并患病率约为0.41(95%CI 0.35–0.48),亚洲高于美洲和欧洲,且2011年后发表的研究患病率高于2000–2010年。
要点
- DM、PM及临床无肌病性皮肌炎亚型ILD合并患病率分别为0.42、0.35和0.53。
- 抗Jo-1和抗MDA5抗体阳性患者较其他肌炎特异性抗体更易发生ILD。
核心结论
- 全球PM/DM患者ILD合并患病率约为41%,以亚洲人群为主,提示遗传与环境差异可能参与ILD发病。
研究设计与样本
- 系统文献综述纳入2000年1月1日至2020年4月30日发表的34项研究、共10,130例PM/DM患者,采用随机效应模型合并患病率,并通过亚组分析和敏感性分析评估异质性。
主要发现
- 全球PM/DM患者ILD合并患病率为0.41(95%CI 0.35–0.48)。
- 2000–2010年、2011–2015年、2016–2020年发表研究的ILD患病率分别为0.27(95%CI 0.16–0.39)、0.43(95%CI 0.34–0.52)、0.45(95%CI 0.35–0.54)。
- DM、PM及临床无肌病性皮肌炎亚型ILD合并患病率分别为0.42(95%CI 0.35–0.49)、0.35(95%CI 0.27–0.42)、0.53(95%CI 0.32–0.74)。
- 抗Jo-1和抗黑色素瘤分化相关基因5(MDA5)抗体阳性患者较其他肌炎特异性抗体更易发生ILD。
关键数值与推荐
- PM/DM患者ILD全球合并患病率0.41(95%CI 0.35–0.48)。
- DM、PM、临床无肌病性皮肌炎亚型患病率分别为0.42(95%CI 0.35–0.49)、0.35(95%CI 0.27–0.42)、0.53(95%CI 0.32–0.74)。
临床怎么用
- 在PM/DM患者中应关注ILD筛查,尤其亚洲人群及抗Jo-1、抗MDA5抗体阳性者。
- 临床无肌病性皮肌炎亚型ILD患病率较高,需加强肺部评估。
局限性
- 研究间异质性高,采用随机效应模型合并患病率。
- 患病率随地理区域和时间趋势变化,需更多研究阐明具体关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Interstitial lung disease (ILD) is the most important prognostic factor for mortality in patients with polymyositis (PM) and dermatomyositis (DM), but the prevalence of ILD in PM/DM may vary between countries. The aim of this study was to determine the overall prevalence of ILD in global patients with PM/DM. METHODS: We performed a systematic literature review of studies published from Jan 1, 2000 to April 30, 2020 on ILD and PM/DM. We extracted data and pooled the prevalence by using a random-effect model due to high heterogeneity. Heterogeneity was assessed by subgroup analysis and sensitivity analysis. RESULTS: A total of 34 studies with 10,130 patients were included in our meta-analysis. Pooled data demonstrated that the global prevalence of ILD in patients with PM/DM was 0.41 (95% confidence interval [CI] 0.35-0.48). However, this prevalence varied with geographical locations and time trends. The prevalence of ILD in PM/DM was 0.5 (95% CI 0.42-0.57) in Asia, 0.23 (95% CI 0.15-0.31) in America, and 0.26 (95% CI 0.18-0.34) in Europe. A higher prevalence of ILD was reported in studies published in 2011-2015 (0.43, 95% CI 0.34-0.52) and 2016-2020 (0.45, 95% CI 0.35-0.54), compared with those published in 2000-2010 (0.27, 95% CI 0.16-0.39). The pooled prevalence of ILD in patients with DM, PM, and clinically amyopathic dermatomyositis subtype was 0.42 (95% CI 0.35-0.49), 0.35 (95% CI 0.27-0.42), and 0.53 (95% CI 0.32-0.74), respectively. Patients with anti-Jo-1 and anti-melanoma differentiation-associated gene 5 antibodies were more likely to develop ILD than other myositis-specific autoantibodies. CONCLUSION: The global prevalence of ILD in patients with PM/DM was approximately 41% and the condition was predominant in Asians. This highlights potential genetic and environmental differences in the pathogenesis of ILD in patients with PM/DM. More studies are required to elucidate the specific associations.
引用
- Sun KY, Fan Y, Wang YX, et al. Prevalence of interstitial lung disease in polymyositis and dermatomyositis: A meta-analysis from 2000 to 2020. Semin Arthritis Rheum. 2020. PMID: 33383294. doi:10.1016/j.semarthrit.2020.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。